Video

Dr. Tap on the Effects of the COVID-19 Pandemic on Sarcoma

William D. Tap, MD, discusses the effects of the COVID-19 pandemic on the treatment of patients with sarcoma.

William D. Tap, MD, chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses the effects of the COVID-19 pandemic on the treatment of patients with sarcoma.

The treatment of patients with sarcoma was significantly affected by the COVID-19 pandemic, says Tap. Questions that arose during the height of the pandemic included how to appropriately continue patient care, how patients with cancer are affected by COVID-19, how to safely and remotely manage patients with cancer, and how to continue clinical research safely, Tap explains. Additionally, investigators in the field of sarcoma are trying to understand how COVID-19 affects patients based on the different types of treatments they receive, including chemotherapies, alkylating agents, anthracyclines, and targeted therapies, Tap adds.

Ultimately, these questions remain less understood in sarcoma compared with other more common tumor types, Tap says. The hope is that enough data will be available from patients with sarcoma to draw conclusions about how the COVID-19 pandemic affected this patient population, concludes Tap.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.